In 2017 the first state contract was conducted with Biocad. The aim of the contract is supply of medicines including counter-investment obligations of the supplier. Biocad is obliged to establish medicine production in Moscow. Main support measures are long-term sales guarantees, inclusion in the register of sole suppliers.
The contract was concluded for 10 years, the cost is 14 million rubles, investments in the project will amount to 3 billion rubles.The project was implemented by the creation of a subsidiary company LLC PK-137, which received the status of resident of the Technopolis, with appropriate benefits.